Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2017-03-17 | Dr. Oesterle is a consultant and provides advisory services to private equity and operating companies in the healthcare industry. The Quality, Compliance and Technology Committee is currently composed of Carole J. Shapazian (Chair), Thomas F. Chen, James R. Gavin III, M.D., Ph.D., Stephen N. Oesterle, M.D. and Albert P.L. Stroucken. |
| 2018-03-23 | Dr. Oesterle is a consultant ... Committees: Corporate Governance and Quality, Compliance and Technology. ... 2017 compensation for non-employee directors: $333,694. |
| 2019-03-26 | Dr. Oesterle is a consultant and provides advisory services to private equity and operating companies in the healthcare industry. ... Committees: Corporate Governance and Quality, Compliance and Technology. ... Director Compensation Table shows total compensation of $320,100. |
| 2020-03-17 | Dr. Oesterle is a consultant advising private equity and operating companies in the healthcare industry. ... Committees: Corporate Governance and Quality, Compliance and Technology. ... Director Compensation Table shows total compensation of $324,757. |
| 2021-03-22 | Dr. Oesterle is a consultant ... Committees: Nominating, Corporate Governance & Public Policy, and Quality, Compliance and Technology. 2020 compensation: $359,962. |
| 2022-03-21 | Dr. Oesterle is a consultant advising private equity and operating companies in the healthcare industry. Committees: Nominating, Corporate Governance & Public Policy and Quality, Compliance and Technology. |
| 2023-03-23 | Extensive experience in the medical products and healthcare industries with a strong scientific and medical background. |
| 2024-03-25 | Dr. Oesterle is a consultant, advising private equity and operating companies in the healthcare industry. ... Committees: Nominating, Corporate Governance and Public Policy and Quality and Regulatory Compliance ... Director Compensation Table shows total compensation of $373,977. |
| 2025-03-25 | Stephen N. Oesterle, M.D. Independent Director Age 74 Director since 2017 Committees: Nominating, Corporate Governance and Public Policy and Quality and Regulatory Compliance Biography Dr. Oesterle is a consultant, advising private equity and operating companies in the healthcare industry. From 2002 to 2015, he was a member of the Executive Committee of Medtronic, a global medical technology, services and solutions company, serving as Medtronic’s Senior Vice President, Medicine and Technology. Previously, he served as an Associate Professor of Medicine and Director of Invasive Cardiology Services at each of Massachusetts General Hospital (1998 to 2002), Stanford University Medical Center (1992 to 1998) and Georgetown University Medical Center (1991 to 1992). Dr. Oesterle currently serves as a director of Paragon 28 and Peijia Medical Ltd. He previously served as a director of Sigilon Therapeutics, Inc., Montes Archimedes Acquisition Corp. and REVA Medical, Inc. Key Attributes, Experience and Skills Extensive experience in the medical products and healthcare industries with a strong scientific and medical background and significant experience advising on strategic transactions. Substantial knowledge of the medical device industry and extensive medical and leadership experience as a result of his role as Senior Vice President, Medicine and Technology at Medtronic and as a director at various healthcare companies as well as positions held at Harvard Medical School, Stanford University Medical Center and other leading hospitals. |
Data sourced from SEC filings. Last updated: 2025-07-01